The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLPE.L Regulatory News (SLPE)

  • There is currently no data for SLPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Quarterly Investment Update at 30 June 2021

29 Sep 2021 07:00

RNS Number : 2479N
Standard Life Private Eqty Trst PLC
29 September 2021
 

 

Standard Life Private Equity Trust plc

Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13

 

 

1. Investment update for the quarter ended 30 June 2021

 

· The net asset value ("NAV") per ordinary share of Standard Life Private Equity Trust plc ("the Company") increased by 10.9% to 630.6 pence for the quarter ended 30 June 2021

· Realised gains and income from portfolio distributions during the quarter ended 30 June 2021 totalled £31.3 million (3.6% of NAV). The unrealised gain on a constant exchange rate basis from ongoing operations was £66.7 million (7.6% of NAV). In addition, there were unrealised foreign exchange gains of £5.5 million (0.6% of NAV)

· The first interim dividend for the financial year ending 30 September 2021 of 3.4 pence per share was paid on 23 April 2021

· 100.0% by value of the portfolio was valued by the respective underlying managers at 30 June 2021

· NAV total return was 11.7% for the three months from 1 April 2021 to 30 June 2021

· Outstanding commitments were £517.1 million at 30 June 2021

· Cash and cash equivalents were £70.1 million at 30 June 2021

 

For the quarter ended 30 June 2021, the Company's NAV increased by 10.9% to 630.6 pence per share from 568.4 pence per share at 31 March 2021. At 30 June 2021, the Company's net assets were £969.5 million (31 March 2021 - £873.9 million). NAV total return was 11.7% for the three months from 1 April 2021 to 30 June 2021. On 23 April 2021, the Company paid the first interim dividend for the year ending 30 September 2021 of 3.4 pence per ordinary share. The cost of the dividend was £5.2 million.

 

The closing value of the Company's portfolio, which included 76 private equity interests, was £899.2 million at 30 June 2021 (31 March 2021 - £804.9 million and 72 private equity interests). 100.0% by value of the portfolio valuations were dated 30 June 2021.

 

The total unrealised gain on the portfolio for the quarter ended 30 June 2021 was £72.2 million (8.2%), comprising £66.7 million (7.6%) of unrealised gain on a constant exchange rate basis and £5.5 million (0.6%) of unrealised foreign exchange gains. The capital movement of the FTSE All-Share Index (in sterling) was an increase of 5.5% during the quarter. The unrealised foreign exchange gains were driven by an appreciation of the Euro by 0.8%, partially offset by the US Dollar depreciating by 0.1% relative to sterling over the quarter.

 

During the quarter ended 30 June 2021, the portfolio generated £45.4 million of distributions (quarter ended 31 March 2021 - £47.5 million). The Company funded £30.2 million of drawdowns (quarter ended 31 March 2021 - £18.5 million) and paid £7.2 million for secondary purchases (quarter ended 31 March 2021 - £nil) into the portfolio. The portfolio distributions received during the quarter generated £31.3 million (3.6%) of net realised gains and income. This was equivalent to a return of 3.2 times the acquisition cost of the realised investments. Separately to the above, the Company received in July £1.1 million of proceeds following the disposal of investment interests through secondary sale during the quarter.

 

In April 2021, the Company acquired through secondary purchase, original commitments of €3.0 million and €8.0 million to Capiton IV and Capiton V respectively. The Company assumed outstanding commitments of €0.2 million and €1.2 million on acquisition.

 

In June 2021, new primary commitments were made to Permira Growth Opportunities II ($35.0 million), Excellere Capital Fund IV ($35.0 million) and Nordic Capital Evolution Fund (€30.0 million) in June. The Company also made a €4.9 million co-investment into KD Pharma, a specialised manufacturer of highly purified Omega-3 fatty acids used as ingredients in the pharmaceuticals and nutraceuticals industries. The co-investment was made alongside sponsor capiton AG.

 

In that same month, the Company sold interests in Equistone Partners Europe Fund III and Terra Firma Capital Partners III for a combined consideration of €1.3 million. The sales price is equivalent to a 7.0% discount of the 30 September 2020 reference date valuation, adjusted for subsequent cash flows. These fund interests had outstanding commitments of €1.6 million and €0.1 million respectively prior to the date of sale.

 

The Company had £517.1 million of outstanding commitments at 30 June 2021. The Manager believes that around £49.1 million of the Company's existing outstanding commitments at that date were unlikely to be drawn.

 

The Company had cash and cash equivalents of £70.1 million at 30 June 2021 (31 March 2021 - £62.5 million). In addition, the Company has an undrawn £200.0 million syndicated revolving credit facility, provided by Citi, Societe Generale and State Street Bank International, that expires in December 2024.

 

 

2. Activity since 30 June 2021

 

On 30 July 2021, the Company paid the second interim dividend for the year ending 30 September 2021 of 3.4 pence per ordinary share. The cost of the dividend was £5.2 million. In addition, the Company declared the third interim dividend for the year ending 30 September 2021 of 3.4 pence per ordinary share, to be paid on 29 October 2021, to shareholders on the Company's share register as at 24 September 2021.

 

During the period from 1 July 2021 to 15 September 2021 the Company received £44.1 million of distributions and funded £38.0 million of drawdowns and co-investment funding.

 

New primary commitments were made to Advent Global Technology II ($31.5 million) and ArchiMed MED III (€15.0 million) during the month of July. The Company also at that time made commitments to three co-investments, being Wundex (€10.0 million), Questel (€10.0 million) and a currently undisclosed consumer health business (€10.0 million). Wundex is a leading German wound care management business which was made alongside sponsor capiton AG. Questel is a leading global player in the IP software and services market which was made alongside sponsor IK Investment Partners. Finally, the consumer health business was made alongside sponsor ArchiMed SaS.

 

In August, the Company made a €10.5 million commitment to Eurazeo Payment Luxembourg Fund SCSp, a single asset vehicle that will invest into Planet, a global integrated payments provider. A $10.0 million co-investment has also made into Insightsoftware, a leading "office of the CFO" software provider. The co-investment was made alongside sponsor Hg.

 

In September, the Company made a $62.5 million commitment to Structured Solutions IV Primary Holdings, a diversified secondary transaction which comprises a balanced portfolio of recent vintage large cap buyout funds in Europe and North America. A €7.9 million co-investment has also made into Riskalyze, a US sector leader in risk tolerance software for financial advisors. The co-investment was made alongside sponsor Hg.

 

The Company had cash and cash equivalents of £65.8 million at 15 September 2021. In addition, the Company had an undrawn £200.0 million syndicated revolving credit facility, provided by Citi, Societe Generale and State Street Bank International, that expires in December 2024. The Company also had total outstanding commitments of £603.2 million. The Manager believes that around £50.2 million of the Company's outstanding commitments are unlikely to be drawn.

 

 

3. Update from the Manager

 

The latest update from the Manager is available within the Latest News section of the Company website; www.slpet.co.uk.

 

 

4. Future Announcements

 

The Company's estimated NAV at 31 August 2021 is also being announced today. The Company's estimated NAV at 30 September 2021 is due to be announced on or around 14 October 2021.

 

For further information please contact:-

 

Alan Gauld at SL Capital Partners LLP (0131 528 4424)

 

Note:-

Standard Life Private Equity Trust plc is an investment company managed by SL Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under sections 1158-1165 of the Corporation Tax Act 2010. The Board of Standard Life Private Equity Trust plc is independent of abrdn plc and Phoenix Group Holdings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDKFBQDBKDFCB
Date   Source Headline
10th Apr 201410:41 amRNSHolding(s) in Company
2nd Apr 201410:07 amRNSDirector Declaration
1st Apr 201411:39 amRNSTotal Voting Rights
19th Mar 20147:00 amRNSQuarterly Trading Statement
3rd Mar 201410:00 amRNSTotal Voting Rights
3rd Feb 201412:20 pmRNSTransaction in Own Shares
3rd Feb 201410:58 amRNSTotal Voting Rights
29th Jan 20144:05 pmRNSTransaction in Own Shares
28th Jan 20142:29 pmRNSHolding(s) in Company
28th Jan 20142:27 pmRNSInterim Management Statement
28th Jan 20142:22 pmRNSResult of AGM
24th Jan 20144:41 pmRNSTransaction in Own Shares
2nd Jan 201412:01 pmRNSQuarterly Disclosure
2nd Jan 201411:59 amRNSTotal Voting Rights
31st Dec 20139:55 amRNSApplication for Listing
11th Dec 20134:51 pmRNSTransaction in Own Shares
4th Dec 20134:31 pmRNSAnnual Financial Report
28th Nov 20137:00 amRNSPreliminary Results
31st Oct 20132:40 pmRNSApplication for Listing
1st Oct 20139:57 amRNSQuarterly Disclosure
23rd Sep 201311:48 amRNSDirector Declaration
18th Sep 20137:00 amRNSQuarterly Trading Statement
1st Aug 20137:30 amRNSTotal Voting Rights
11th Jul 20136:14 pmRNSHolding(s) in Company
8th Jul 201312:28 pmRNSInterim Management Statement
1st Jul 201310:58 amRNSQuarterly Disclosure
28th Jun 201311:46 amRNSApplication for Listing
21st Jun 20139:47 amRNSDirector Declaration
11th Jun 20134:03 pmRNSDirectorate Change
3rd Jun 20131:58 pmRNSDirectorate Change
29th May 20135:00 pmRNSHalf Yearly Report
2nd Apr 201311:43 amRNSQuarterly Disclosure
2nd Apr 201311:40 amRNSTotal Voting Rights
26th Mar 20134:58 pmRNSTransaction in Own Shares
20th Mar 20134:05 pmRNSDirector/PDMR Shareholding
20th Mar 20137:00 amRNSQuarterly Trading Statement
18th Mar 20133:25 pmRNSHolding(s) in Company
8th Feb 20132:41 pmRNSDirector/PDMR Shareholding
5th Feb 20131:20 pmRNSDirector/PDMR Shareholding
1st Feb 201311:33 amRNSTotal Voting Rights
29th Jan 20134:37 pmRNSInterim Management Statement
29th Jan 20131:52 pmRNSIssue of Equity
29th Jan 20131:48 pmRNSResult of AGM
29th Jan 20131:47 pmRNSDirectorate Changes
9th Jan 20134:29 pmRNSScrip dividend reference price
4th Jan 201312:22 pmRNSQuarterly Disclosure
3rd Jan 201311:21 amRNSDirector/PDMR Shareholding
31st Dec 20128:00 amRNSApplication for Listing
31st Dec 20128:00 amRNSDebt Facility
14th Dec 201212:15 pmRNSDoc re. Annual Report and Circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.